DS
EWTX icon

David Shaw’s Edgewise Therapeutics EWTX Stock Holding History

David Shaw’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.68M Buy
189,115
+84,252
+80% +$2.9M ﹤0.01% 2049
2026
Q1 		$3.3M Sell
104,863
-289,832
-73% -$8.36M ﹤0.01% 2505
2025
Q4 		$9.79M Sell
394,695
-282,866
-42% -$5.68M 0.01% 1773
2025
Q3 		$11M Buy
677,561
+82,129
+14% +$1.16M 0.01% 1603
2025
Q2 		$7.81M Buy
595,432
+454,884
+324% +$6.56M 0.01% 1685
2025
Q1 		$3.09M Sell
140,548
-545,823
-80% -$14.3M ﹤0.01% 2273
2024
Q4 		$18.3M Buy
686,371
+231,023
+51% +$7.36M 0.01% 1084
2024
Q3 		$12.2M Buy
455,348
+143,872
+46% +$2.86M 0.01% 1289
2024
Q2 		$5.61M Sell
311,476
-162,204
-34% -$2.83M 0.01% 1760
2024
Q1 		$8.64M Buy
473,680
+441,730
+1,383% +$7.02M 0.01% 1472
2023
Q4 		$350K Buy
+31,950
New +$224K ﹤0.01% 3681
2023
Q2 		– Sell
-24,736
Closed -$165K – 4324
2023
Q1 		$165K Buy
24,736
+13,462
+119% +$125K ﹤0.01% 3940
2022
Q4 		$101K Buy
+11,274
New +$106K ﹤0.01% 4362
2021
Q4 		– Sell
-13,695
Closed -$227K – 5489
2021
Q3 		$227K Sell
13,695
-32,472
-70% -$587K ﹤0.01% 4508
2021
Q2 		$985K Buy
+46,167
New +$1.26M ﹤0.01% 3555

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's EWTX Position: Q2 2026 in Review

David Shaw increased its Edgewise Therapeutics (EWTX) stake by 80% in Q2 2026, buying an estimated $2.9M and bringing the position to 189,115 shares worth $7.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2049.

David Shaw first reported a position in EWTX in Q2 2021 and has held it in 15 quarters since. The position peaked at $18.3M in Q4 2024. 224 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • David Shaw held 189,115 shares of Edgewise Therapeutics worth $7.68M as of Q2 2026.
  • David Shaw bought 84,252 Edgewise Therapeutics shares in Q2 2026, an estimated $2.9M.
  • Edgewise Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2049 holding.
  • David Shaw first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • David Shaw's Edgewise Therapeutics position peaked at $18.3M in Q4 2024.
  • 224 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.